Novel Therapeutic Combinations with PARP Inhibitors for Small Cell Lung Cancer: A Bench-to-Bedside Review

The authors summarize existing preclinical evidence supporting inhibitors of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) monotherapy, combination therapy, and respective translation to the clinic.